Table 1 (abstract P188). Descriptors of subcutaneous tocilizumab treatment in the cohort
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
Age at SC-TCZ onset | 21.5 ± 7.5 (6.3-33.2) years |
Duration of uveitis at SC-TCZ onset | 17.4 ± 7.1 (4-26.6) years |
Duration of SC-TCZ therapy | 2.6 ± 1.9 (0.6-5.5) years |
Flare/year rate on SC-TCZ | 0.4 ± 0.7 |
Flare/year rate on bDMARDs before SC-TCZ | 1.6 ± 2.0 |